Finally, we provide evidence suggesting that inhibition of β-Catenin by either small molecule inhibitors ICG-001 or PRI-724 or a LEF1/TCF oligonucleotide-based PROTAC represents a viable strategy not only suitable for effective treatment of ERG/GOF mutant p53-positive PCa, but also possibly for other cancer types such as the hematologic malignancies and solid tumors expressing GOF mutant p53 protein. Here, ERG is linked to cancer.